Description of Invention:
This invention is directed to a "humanized" polynucleotide vector vaccine which
uses covalent closed circular (CCC) plasmid DNA, "naked DNA," to express target
antigens. The vector contains the necessary elements to express mRNA for a target antigen. The plasmids are non-replicating but are capable of extended stable expression of the target sequences in skeletal muscle and professional antigen presenting cells generating an immune response to the target antigen in immunized individuals. The polynucleotide vector is particularly useful in accommodating monomorphic and polymorphic tumor antigens via PCR technology. This invention could be useful in constructing polynucleotide vector cancer vaccines or "naked DNA" vaccines containing one or more tumor antigens.
Inventors:
EL Nelson PJ Nelson (NCI)
Patent Status:
DHHS Reference No. E-144-1996/0 Licensing Status: This technology is no longer available for licensing.
Portfolios: Cancer
Cancer -Therapeutics-Gene Therapy-Vectors Cancer -Therapeutics
For Additional Information Please Contact: John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-5236
Email: stansbej@mail.nih.gov
Fax: (301) 402-0220
